APA (7th ed.) Citation

U, L., B, G., D, D. G., D, N., S, A. P., B, G., . . . LTH, J. (2019). Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. RMD open, 5(2), e001079. https://doi.org/10.1136/rmdopen-2019-001079

Chicago Style (17th ed.) Citation

U, Lindström, et al. "Treatment Retention of Infliximab and Etanercept Originators Versus Their Corresponding Biosimilars: Nordic Collaborative Observational Study of 2334 Biologics Naïve Patients with Spondyloarthritis." RMD Open 5, no. 2 (2019): e001079. https://doi.org/10.1136/rmdopen-2019-001079.

MLA (9th ed.) Citation

U, Lindström, et al. "Treatment Retention of Infliximab and Etanercept Originators Versus Their Corresponding Biosimilars: Nordic Collaborative Observational Study of 2334 Biologics Naïve Patients with Spondyloarthritis." RMD Open, vol. 5, no. 2, 2019, p. e001079, https://doi.org/10.1136/rmdopen-2019-001079.